This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2020 Dec 24;383(26):2557-2570.

doi: 10.1056/NEJMra1307118.

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Harold J Burstein¹

Affiliations

PMID: 33369357
DOI: 10.1056/NEJMra1307118

Review

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Harold J Burstein. N Engl J Med. 2020.

. 2020 Dec 24;383(26):2557-2570.

doi: 10.1056/NEJMra1307118.

Author

Harold J Burstein¹

Affiliation

¹ From the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School - all in Boston.

PMID: 33369357
DOI: 10.1056/NEJMra1307118

No abstract available

PubMed Disclaimer

Comment in

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Copur MS. Copur MS. N Engl J Med. 2021 Mar 25;384(12):1176. doi: 10.1056/NEJMc2101282. N Engl J Med. 2021. PMID: 33761225 No abstract available.

Similar articles

The evolving use of SERDs in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Jeselsohn RM. Jeselsohn RM. Clin Adv Hematol Oncol. 2021 Jul;19(7):428-431. Clin Adv Hematol Oncol. 2021. PMID: 34236340 No abstract available.
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Ohno S. Ohno S. Clin Breast Cancer. 2016 Aug;16(4):238-46. doi: 10.1016/j.clbc.2016.03.001. Epub 2016 Mar 12. Clin Breast Cancer. 2016. PMID: 27151773 Review.
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK, Bihani T. Patel HK, et al. Pharmacol Ther. 2018 Jun;186:1-24. doi: 10.1016/j.pharmthera.2017.12.012. Epub 2017 Dec 28. Pharmacol Ther. 2018. PMID: 29289555 Review.
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Yu KD, Wu SY, Liu GY, Wu J, Di GH, Hu Z, Hou YF, Chen CM, Fan L, Tang LC, Shen ZZ, Wu KJ, Zhuang ZG, Zhang HW, Shao ZM. Yu KD, et al. Cancer. 2019 Jul 1;125(13):2185-2193. doi: 10.1002/cncr.32057. Epub 2019 Mar 20. Cancer. 2019. PMID: 30892700 Clinical Trial.
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO. Rydén L, et al. Breast Cancer Res Treat. 2008 May;109(2):351-7. doi: 10.1007/s10549-007-9660-2. Epub 2007 Jul 18. Breast Cancer Res Treat. 2008. PMID: 17636399 Clinical Trial.

See all similar articles

Cited by

Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine.
Knöbl V, Maier L, Grasl S, Kratzer C, Winkler F, Eder V, Hayden H, Sahagun Cortez MA, Sachet M, Oehler R, Frantal S, Fesl C, Zehetner K, Pfeiler G, Bartsch R, Fitzal F, Singer CF, Filipits M, Gnant M, Brostjan C. Knöbl V, et al. J Transl Med. 2024 Oct 8;22(1):913. doi: 10.1186/s12967-024-05659-w. J Transl Med. 2024. PMID: 39380101 Free PMC article.
Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer.
Hsu E, Arezo SM, Graff SL. Hsu E, et al. Curr Treat Options Oncol. 2024 Oct;25(10):1323-1334. doi: 10.1007/s11864-024-01258-5. Epub 2024 Oct 3. Curr Treat Options Oncol. 2024. PMID: 39361142 Review.
A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells.
da Silva FC, Martinho ACC, Ferreira HSV, Siqueira RP, Arruda VM, Guerra JFDC, de Souza MLDR, Landin ES, Rezende Júnior CO, de Araújo TG. da Silva FC, et al. Molecules. 2024 Sep 20;29(18):4471. doi: 10.3390/molecules29184471. Molecules. 2024. PMID: 39339466 Free PMC article.
Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis.
Zhang Z, Zhao X, Chen J. Zhang Z, et al. Front Pharmacol. 2024 Sep 12;15:1438288. doi: 10.3389/fphar.2024.1438288. eCollection 2024. Front Pharmacol. 2024. PMID: 39329126 Free PMC article.
Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.
Xu Y, Qi Y, Lu Z, Tan Y, Chen D, Luo H. Xu Y, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2405060. doi: 10.1080/15384047.2024.2405060. Epub 2024 Sep 20. Cancer Biol Ther. 2024. PMID: 39304993 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal